Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

• ClinicalTrials.gov Identifier: NCT02436993
• Recruitment Status: Recruiting
• First Posted: May 7, 2015
• Last Update Posted: July 2, 2020
• Sponsor: University of California, Irvine
• Information provided by (Responsible Party): Rita Sanghvi, Mehta, University of California, Irvine

Study Description

Brief Summary:

The purpose of this phase II is to study the efficacy and toxicity of carboplatin and paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel with bevacizumab in HER2 negative in the neoadjuvant setting for the treatment of breast cancer.

Condition or disease	Intervention/treatment	Phase
Breast Carcinoma	Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab; Drug: Trastuzumab; Drug: Pertuzumab	Phase 2

Detailed Description:

OBJECTIVES The study component is to evaluate the treatment response and toxicity of the protocol.

Objectives for treatment study component:

1.1 To estimate 2-year progression-free survival in patients with breast cancer with tumor more than 1 cm and/or with clinically detected lymph node treated with neoadjuvant weekly Carboplatin and Paclitaxel combined with Trastuzumab + Pertuzumab in HER2-positive disease or with Bevacizumab in HER2-negative disease.

1.2 To measure the microscopic complete pathological response (pCR) rates defined as ypT0 or ypTis tumors in patients treated with this regimen in the neoadjuvant setting.

1.3 To assess complete clinical response (cCR) rates after treatment by physical exam and imaging tests (ultrasonography, mammography, or magnetic resonance imaging) clinical objective response rate (by Response Evaluation Criteria In Solid Tumors (RECIST)) 1.4 To determine the toxicity of this regimen. 1.5 To determine treatment adherence and delivered dose intensity of this regimen.

1.6 To assess the correlation between pCR and cCR. 1.7 To determine the rate of breast conservation following neoadjuvant therapy. 1.8 Determine treatment efficacy according to subgroups defined according to stage and receptor status.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 120 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
• Study Start Date: April 2015
• Estimated Primary Completion Date: August 2040
• Estimated Study Completion Date: August 2040

Arms and Interventions

Arm	Intervention/treatment
Experimental: Carboplatin+Paclitaxel+Bevacizumab (HER2-); Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses	Drug: Carboplatin; Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses; Other Name: Paraplatin; Drug: Paclitaxel; 80 mg/m^2 IV over 1-3 hours weekly for 12 doses; Other Name: Taxol; Drug: Bevacizumab; 10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses; Other Name: Avastin
Experimental: Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+); Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses	Drug: Carboplatin; Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses; Other Name: Paraplatin; Drug: Paclitaxel; 80 mg/m^2 IV over 1-3 hours weekly for 12 doses; Other Name: Taxol; Drug: Trastuzumab; 4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses; Other Name: Herceptin; Drug: Pertuzumab; 840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses; Other Name: Perjeta

Outcome Measures

Primary Outcome Measures :

1. 2-year progression free survival in patients treated with weekly carboplatin and paclitaxel combined with either trastuzumab and pertuzumab for HER2-positive patients or bevacizumab for HER2-negative patients in the neoadjuvant setting [ Time Frame: 2 years ]
   Progression of disease-A new lesion or a greater than or equal to 25% increase in the product of the largest perpendicular diameters of any one lesion on clinical exam or by U/S or MRI Survival-from date of registration to date of death

Secondary Outcome Measures :

1. Clinical complete response rates [ Time Frame: 2 years ]
   Clinical complete response (cCR)-Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange
2. Pathologic complete response rates [ Time Frame: 2 years ]
   Pathologic complete response (pCR)-No histologic evidence of microscopic invasive tumor at the primary tumor site in the surgical specimen (ypT0 or DCis)
3. Number of toxicities in Carboplatin+Paclitaxel+Bevacizumab (HER2) arm [ Time Frame: Up to 42 days after discontinued treatment ]
   This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.
4. Number of toxicities in Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+) [ Time Frame: Up to 42 days after discontinued treatment ]
   This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Histologically proven unilateral or bilateral primary breast carcinoma. (In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.)
2. Tumor size is clinically at least 1 cm in greatest diameter (palpable or by imaging) and/or with involved lymph node. In case of inflammatory disease, the extent of inflammation may be the measurable lesion.
3. Documentation of inflammatory breast cancer
4. Woman age > or = 18
5. Performance status of 0-2 by Eastern Cooperative Oncology Group (ECOG) criteria
6. Known HER2 status

7. Normal cardiac function must be documented within 90 days prior to registration. Result of ejection fraction must be above the normal limit of the institution. Echo or MUGA is encouraged pre-study.

   a. Date of Echo or multigated acquisition (MUGA) (within 90 days)

8. Staging work-up prior to registration

   1. Date of physical examination (within 90 days)
   2. Date of bilateral mammogram (within 90 days)
   3. Date of breast ultrasound (within 90 days)
   4. Date of MRI breast (within 30 days)
   5. Chest X-ray or CT-Chest or CT/PET Scan that includes the Chest is also accepted (within 90 days)
   6. Other tests as clinically indicated

9. Laboratory requirements:

   1. Hematology:

      • Absolute Neutrophil Count (ANC) ≥ 1,500/μl
      • Platelets ≥ 100,000/μl

   2. Hepatic Function

      • Total Bilirubin <1x upper limit of normal (ULN)
      • aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2x ULN

   3. Renal Function

      - Creatinine <1.5x ULN

   4. Proteinuria

      - Urine dipstick for proteinuria <2+. Patients discovered to have ≥2+ proteinuria on dipstick should undergo a 24-hour urine collection and demonstrate ≤ 1g of protein in 24 hours.

   5. Negative pregnancy test for women of childbearing potential within 14 days prior to registration.

10. All patients must be informed of the investigational nature of this study and must sign and\give written informed consent in accordance with institutional and federal guidelines.

    Exclusion Criteria:

11. Evidence of distant metastasis
12. Known or suspected congestive heart failure, angina pectoris requiring antianginal medication, or other clinically significant cardiac condition.
13. Pregnant or nursing women may not participate due to the possibility of harm to fetus or nursing infants from this treatment regimen. Women of childbearing potential may not participate unless they have agreed to use an adequate contraceptive method throughout study treatment and for one month after completion of treatment.
14. Male patients
15. Pre-existing peripheral neuropathy of severity grade ≥ 2 (limiting instrumental activities of daily living).
16. Incomplete wound healing.
17. Active and significant bleeding
18. Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol.
19. Bone marrow depression or hematologic parameters in the range that would increase the risk for severe bleeding.

Contacts and Locations

Contacts

Contact: UC Irvine Health Chao Family Comprehensive Cancer Center; 1-877-UC-STUDY; UCstudy@uci.edu

Locations

United States, California

UC Irvine Health/Chao Family Comprehensive Cancer Center; Recruiting

Orange, California, United States, 92868

Contact: Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center 877-827-8839 UCstudy@uci.edu

Sponsors and Collaborators

University of California, Irvine

Investigators

• Principal Investigator: Rita Mehta, MD; University of California, Irvine

More Information

• Responsible Party: Rita Sanghvi, Mehta, HS Clinical Professor, University of California, Irvine
• ClinicalTrials.gov Identifier: NCT02436993
• Other Study ID Numbers: UCI 14-67; 2015-1888 ( Other Identifier: University of California, Irvine )
• First Posted: May 7, 2015
• Last Update Posted: July 2, 2020
• Last Verified: June 2020

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Rita Sanghvi, Mehta, University of California, Irvine:

Neoadjuvant Treatment; Carboplatin; Paclitaxel; Pertuzumab; Trastuzumab; Bevacizumab

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Paclitaxel; Bevacizumab; Carboplatin; Trastuzumab; Pertuzumab; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Physiological Effects of Drugs; Growth Inhibitors